P&G Intrinsa Need For Longer-Term Safety Data To Be Examined By Reproductive Cmte.

FDA will ask committee whether Intrinsa testosterone patch needs more safety data in women receiving estrogen prior to approval. Procter & Gamble is proposing a pharmacovigilance study to follow emerging adverse events with the female sexual dysfunction drug.